iShares iBonds 2036年12月期公債ETF IBTR 深 滬
已收盤 05-22 16:00:00 美东时间
24.65
+0.035
+0.14%
華盛通- 最 高24.658
- 今 開24.65
- 成交量 1.82万股
- 最 低 24.60
- 昨 收 24.615
- 總市值 616.25万
- 52周最高 25.161
- 市盈率 靜 --
- 換手率 7.29%
- 52周最低 24.39
- 委 比 23.08%
- 總股本 25.00万
- 歷史最高 25.161
- 量 比 2.23
- 振 幅 0.24%
- 歷史最低 24.39
- 每 手 1
- 風險率 0.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuvation Bio Reveals IBTROZI Showed Highly Durable Responses in Longer-Term Follow-Up Data From Pivotal Studies Presented At AACR 2026; IBTROZI Also Demonstrated A High Overall Response Rate In TKI-Naïve Patients At 89.8%; Preclinical Data Presented At AACR Showed Taletrectinib's Potential For Suppressing TrkB-mediated Lung Cancer Cell Migration
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the
04-22 06:04
Nuvation Bio, Eisai application for taletrectinib for NSCLC accepted by EMA
The European Medicines Agency has accepted a Marketing Authorisation Application filed by Nuvation Bio (NUVB) and Eisai (ESALF)(ESAIY) for taletrectinib to treat non-small cell lung cancer. The applic...
03-27 05:26
